Paul Polakis

发表

GEPIS - quantitative gene expression profiling in normal and cancer tissues

Yan Zhang, Yan Zhou, Zemin Zhang, 2004, Bioinform..

The oncogenic activation of β-catenin

Paul Polakis, P. Polakis, 1999 .

The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors

Paul Polakis, B. Fingleton, L. Matrisian, 1999, Oncogene.

Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β

Paul Polakis, P. Polakis, I. Albert, 1998, Current Biology.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Paul Polakis, Yanmei Lu, V. Katta, 2008, Nature Biotechnology.

Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines

Paul Polakis, Paul Robbins, P. Robbins, 1997, Science.

EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer

Paul Polakis, H. Koeppen, S. Ross, 2004, Cancer Research.

Wnt signaling in cancer.

Paul Polakis, P. Polakis, 2012, Cold Spring Harbor perspectives in biology.

Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly

Paul Polakis, P. Polakis, E. Porfiri, 1996, Science.

Site-specific antibody drug conjugates for cancer therapy

Paul Polakis, S. Panowski, P. Polakis, 2013, mAbs.

Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers

Paul Polakis, Keyang Xu, Leslie Roth, 2015, Clinical Cancer Research.

Antibody Drug Conjugates for Cancer Therapy

Paul Polakis, P. Polakis, 2016, Pharmacological Reviews.